The changing face of familial Mediterranean fever
Semin Arthritis Rheum. 1996 Dec;26(3):612-27. doi: 10.1016/s0049-0172(96)80012-6.
A Livneh 1 , P Langevitz, D Zemer, S Padeh, A Migdal, E Sohar, M Pras
1 Heller Institute of Medical Research, Sheba Medical Center, Tel-Hashomer, Israel.
Familial Mediterranean fever (FMF) is a genetic disease characterized by painful febrile "attacks" of serositis and the development of amyloidosis. Although FMF has been extensively studied and described, new data have accumulated during the last decade. This report gives an update, focusing specifically on (1) newly characterized manifestations, such as acute scrotal "attacks," protracted febrile myalgia, and spondyloarthropathy; (2) progress made in the diagnosis and treatment of FMF-amyloidosis; (3) experience acquired with colchicine, establishing its safety in common practice, childhood, conception, and pregnancy; (4) colchicine's role in the prevention and treatment of FMF-amyloidosis; (5) new laboratory findings; and (6) new considerations in the differential diagnosis. The most important achievement in recent years, however, is the mapping of the FMF susceptibility gene to chromosome 16p, a finding that raises hopes for prompt cloning of the gene and elucidation of the mechanisms involved in FMF expression.
Familial Mediterranean Fever / diagnosis
Familial Mediterranean Fever / drug therapy
Familial Mediterranean Fever / epidemiology*